Clinical and economic burden of invasive fungal diseases in Europe: focus on pre-emptive and empirical treatment of Aspergillus and Candida species

por Drgona, L., Khachatryan, A., Stephens, J., Charbonneau, C., Kantecki, M., Haider, S., Barnes, R.
Publicado 2013

Cost-effectiveness analysis of anidulafungin in the treatment of candidaemia

por Auzinger, G, Playford, G, Graham, C, Narula, H, Charbonneau, C, Weinstein, D, Kantecki, M, Schlamm, H, Ruhnke, M
Publicado 2013

Anidulafungin for candidemia/invasive candidiasis in non-neutropenic ICU patients

por Ruhnke, M, Paiva, J, Meersseman, W, Pachl, J, Grigoras, I, Sganga, G, Menichetti, F, Montravers, P, Auzinger, G, Dimopoulos, G, Sá, M Borges, Miller, P, Marček, T, Kantecki, M
Publicado 2011

Anidulafungin for the treatment of candidaemia/invasive candidiasis in selected critically ill patients

por Ruhnke, M, Paiva, J A, Meersseman, W, Pachl, J, Grigoras, I, Sganga, G, Menichetti, F, Montravers, P, Auzinger, G, Dimopoulos, G, Borges Sá, M, Miller, P J, Marček, T, Kantecki, M
Publicado 2012